LBP15: SUVN-502 + Donepezil + Memantine (Triple combination) represents a promising new approach for symptomatic treatment of Alzheimer’s disease.
Ramakrishna Nirogi, PhD, Renny Abraham, PhD, Vijay Benade, MS, Pradeep Jayarajan, PhD, Koteswara Mudigonda, PhD, Jyothsna Ravula, MS, Devender Reddy Ajjala, PhD, Ramasastry Kambhampati, PhD, Trinath Reddy Bandyala, PhD and Venkat Jasti MS.
(1) Discovery Research, Suven Life Sciences Ltd, Hyderabad, India

LBP16: Neuroprotective and trophic effects of Bacopa monniera extract protects against amyloid β-peptide and hydrogen peroxide-induced toxicity and oxidative stress
Manjeet Singh and Charles Ramassamy
(1) INRS-Institut Armand Frappier, Laval, Quebec, Canada

LBP17: Phase 1 Study of the Muscarinic M1 Positive Allosteric Modulator VU319 for Alzheimer’s Disease: Exploration of Novel Markers of Target Engagement
Paul A Newhouse, MD,1,2, Alexandra Key, PhD,1, Alexander Conley, PhD,1, Robert Gould, PhD,3, Carrie Jones, PhD
(1) Center for Cognitive Medicine, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center(2) Vanderbilt Kennedy Center, Vanderbilt University(3) Vanderbilt Center for Neuroscience Drug Discovery, Department of Pharmacology, Vanderbilt University

LBP18: Efficacy and safety of the Chinese medicine SaiLuoTong in vascular dementia: A randomised, controlled, double-blind, parallel-arm trial
Jianping Jia, Cuibai Wei, M. D., 1, Shuoqi Chen, M. D., 1, Fangyu Li, M. D., 1, Yi Tang, M. D., 1, Wei Qin, M. D., 1, Lu Shi, M. D., 1, Min Gong, M. D., 1, Hui Xu, M. D., 1, Fang Li, M. D., 1, Jia He, M. D., 1, Haiqing Song, M. D., 1, Shanshan Yang, M. D., 1, Aihong Zhou, M. D., 1, Fen Wang M. D., 1, Xiumei Zuo, M. D., 1, Changbiao Chu, M. D., 1, Junhua Liang, M. D., 1, Longfei Jia, M. D., 1, Serge Gauthier, M. D.
(1) Department of Neurology, Xuan Wu Hospital, Capital Medical University, Beijing, China. (2) Beijing Key Laboratory of Geriatric Cognitive Disorders; Beijing, China. (3) Center of Alzheimer’s Disease, Beijing Institute for Brain Disorders, Beijing, China. (4) Key Laboratory of Neurodegenerative Diseases, Ministry of Education; Beijing, China. (5) National Clinical Research Center for Geriatric Disorders; Beijing, China.,(6) Department of Gerontology, Fuxing Hospital, Capital Medical University, Beijing, China.,(7) Department of Health Statistics, Second Military Medical University, Shanghai, China.,(8) Department of Neurology, Daqing Oilfield General Hospital, China., (9) Department of Neurology, Henry Ford Hospital, Detroit, USA. (10) Centre for Studies in Aging, McGill University, Montreal, CAN.

LBP19: Increased immune signaling predicts mitigation in AD clinical outcomes – an alternate route to prevention.
John Breitner, MD, MPH (1) Douglas Hospital Research Centre, Montreal, QC, Canada; (2) McGill University Faculty of Medicine

LBP20: CHARACTERISTICS OF SLEEP AND WAKEFULNESS MEASURED WITH ACTIGRAPHY IN PATIENTS WITH IRREGULAR SLEEP-WAKE RHYTHM DISORDER AND ALZHEIMER’S DISEASE.
Margaret Moline, PhD, Patricia Murphy, PhD, Gleb Filippov, MD, PhD, Naoki Kubota, MPharm, Mohammad Bsharat, PhD, Manuel Kemethofer, MSc, Andrew Satlin, MD
(1) Eisai, Inc., Woodcliff Lake, NJ, USA (2) Eisai Co., Ltd. Tokyo, Japan (3) The Siesta Group, Vienna, Austria

LBP21: MULTIPLE ASCENDING DOSE STUDY WITH A PRODRUG OF GALANTAMINE: A PHARMACO-EEG ANALYSIS WITH EVIDENCE OF POSITIVE EFFECTS ON COGNITION.
D.G. Kay PhD, E. t’Hart PhD, C. Bakker MD, A. Maelicke PhD, Sonja Simpraga, Klaus Linkenkaer-Hansen, Simon-Shlomo Poil, G.J. Groeneveld MD PhD,
LBP23: Matrix therapy, a novel approach for Alzheimer's disease and related tauopathies
Dulce Papy-Garcia, PhD1 Growth, Repair and Regeneration of Tissues Research Unit (CRRET)-CNRS 9215, Université Paris Est Créteil, Créteil, France Mohand-Ouidir Ouidja, PhD1; Fernando Sineriz, PhD2, Denis Barritault, PhD3
(1) CRRET-CNRS 9215, Université Paris Est Créteil, Créteil, France (2) OTR3, Paris, France

LBP24: ALLOPREGNANOLONE AS A REGENERATIVE THERAPEUTIC FOR ALZHEIMER’S DISEASE: PHASE 1B/2A OUTCOMES
Roberta Diaz Brinton, PhD1, Gerson Hernandez, MD2, Christine Solinsky, PharmD3, Meng Law, MD4, Yonggang Shi, PhD5, Dogu Aydogan, Ph.D.6, Jin Gahm, PhD7, Wendy Mack, PhD8, Naoko Kono, MPH9, Kathleen Rodgers, PhD10, Claudia Lopez11, Ronald Irwin, PhD12, Michael Rogawaski, MD13, Chun-Yi Wu, PhD14, Lon Schneider, MD15,
(1) Center for Innovation in Brain Science, University of Arizona Health Sciences, Tucson, AZ, USA
(2) Center for Innovation in Brain Science, University of Arizona Health Sciences, Tucson, AZ, USA
(3) Department of Clinical & Experimental Therapeutics, University of Southern California, Los Angeles, CA, USA (4) Department of Neuroradiology, University of Southern California, Los Angeles, CA, USA (5) Laboratory of Neuro Imaging, USC Stevens Neuroimaging and Informatics Institute, University of Southern California, Los Angeles, CA, USA (6) Laboratory of Neuro Imaging, USC Stevens Neuroimaging and Informatics Institute, University of Southern California, Los Angeles, CA, USA (7) Laboratory of Neuro Imaging, USC Stevens Neuroimaging and Informatics Institute, University of Southern California, Los Angeles, CA, USA (8) Department of Preventive Medicine, University of Southern California, Los Angeles, CA, USA (9) Department of Preventive Medicine, University of Southern California, Los Angeles, CA, USA (10) Center for Innovation in Brain Science, University of Arizona Health Sciences, Tucson, AZ, USA (11) Center for Innovation in Brain Science, University of Arizona Health Sciences, Tucson, AZ, USA (12) Department of Pharmacology, University of Southern California, Los Angeles, CA, USA (13) Department of Neurology, University of California at Davis, Davis, CA, USA (14) Department of Neurology, University of California at Davis, Davis, CA, USA (15) Department of Psychiatry, University of Southern California, Los Angeles, CA, USA